We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July 10, 2024 Multiple catalysts for potentially transformative assets in second half of...
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution PR Newswire CRANFORD, N.J., May 29, 2024 Management call scheduled...
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution PR Newswire CRANFORD, N.J., May 21, 2024 Trial achieves statistically...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., May 14, 2024 Mino-Lok data analysis on track with...
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences PR Newswire CRANFORD, N.J., May 10, 2024 CRANFORD, N.J., May 10, 2024 /PRNewswire/ -- Citius...
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 30, 2024 CRANFORD, N.J., April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals...
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 26, 2024 CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc...
| Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
